New combo therapy aims to stop mesothelioma return after surgery
NCT ID NCT05932199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving immunotherapy drugs (durvalumab and tremelimumab) alone or with chemotherapy before surgery can help prevent pleural mesothelioma from coming back. About 52 people with potentially removable tumors will take part. The main goal is to see if more than 60% of patients stay cancer-free for at least one year after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immunotherapy drugs) with or without chemotherapy (cisplatin or carboplatin plus pemetrexed)
What this could lead to
If successful, this could offer a new treatment option that delays cancer return after surgery for people with pleural mesothelioma.
What could go wrong
This is an early-phase trial with only 52 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor St Lukes
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke Cancer Institute
NOT_YET_RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••